Author reply to letters received following the phase 2 retatrutide obesity trial publication in NEJM. Addresses questions raised by correspondents about trial design, comparisons with other agents, long-term outcomes, or mechanism, providing additional context or clarification from the investigators.
Jastreboff, Ania M; Kaplan, Lee M; Hartman, Mark L